We will be contrasting the differences between Actinium Pharmaceuticals Inc. (NYSEAMERICAN:ATNM) and Cambrex Corporation (NYSE:CBM) as far as analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings & Valuation

Table 1 showcases the top-line revenue, earnings per share and valuation of Actinium Pharmaceuticals Inc. and Cambrex Corporation.

Profitability

Table 2 hightlights the return on assets, return on equity and net margins of the two companies.

Volatility and Risk

Actinium Pharmaceuticals Inc.’s current beta is 2.29 and it happens to be 129.00% more volatile than Standard and Poor’s 500. Competitively, Cambrex Corporation is 136.00% more volatile than Standard and Poor’s 500, because of the 2.36 beta.

Liquidity

Actinium Pharmaceuticals Inc.’s Current Ratio is 2.4 while its Quick Ratio is 2.4. On the competitive side is, Cambrex Corporation which has a 3 Current Ratio and a 2 Quick Ratio. Cambrex Corporation is better positioned to pay off short and long-term obligations compared to Actinium Pharmaceuticals Inc.

Analyst Recommendations

Actinium Pharmaceuticals Inc. and Cambrex Corporation Ratings and Recommendations are available in the next table.

Meanwhile, Cambrex Corporation’s consensus target price is $49, while its potential upside is 5.58%.

Institutional and Insider Ownership

The shares of both Actinium Pharmaceuticals Inc. and Cambrex Corporation are owned by institutional investors at 9.3% and 0% respectively. Actinium Pharmaceuticals Inc.’s share held by insiders are 0.1%. Competitively, Cambrex Corporation has 1% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Actinium Pharmaceuticals Inc. has -32.82% weaker performance while Cambrex Corporation has 15.97% stronger performance.

Summary

Cambrex Corporation beats on 9 of the 9 factors Actinium Pharmaceuticals Inc.

Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted payload immunotherapeutics for the treatment of advanced cancers. The companyÂ’s proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its lead product candidate is Iomab-B that is in Phase III clinical studies in refractory or relapsed acute myeloid leukemia (AML) patients over the age of 55 for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60; and Actimab-M that is in Phase I clinical trials for patients with relapsed or refractory multiple myeloma. In addition, it utilizes its alpha-particle immunotherapy technology platform to generate new drug candidates based on antibodies linked to the element Actinium-225 that are directed at various cancers that are blood-borne or form solid tumors. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. The companyÂ’s products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals. It serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.